Kornimate/medical-research-clean huggingface dataset:
exercise response on dose curve among class i obese young adult population

Conditions: Obesity

Summary: the study is aimed to determine impact of dynamic resistance exercise training on body fat percentage of class-i obese population and to quantify the dose of exercise program using a probit regression curve

methodology a sample size of 34 participants 17 male and 17 female of aged between 20-40 years with class-i obesity were selected and recruited in this study. all the participants were initially screened using a physical activity and readiness questionnaire to determine if they are fit to perform exercises afterwards intervention based on dynamic exercises were given to the patient for 12 weeks based on the guidelines of american college of sports medicine and the quantification of exercises was done using a frequency, intensity, time and type (fitt) protocol. the training session was based on warm up 5 to 10 minutes followed by conditioning phase of 20 minutes and a cool down phase of 5 to 10 minutes. the detailed description of each of the phase is as under: warm up phase dynamic light aerobic warm up exercises were performed by the participants for 5 to 10 minutes before the start of the conditioning. two different exercises that were performed included i) high knee in which the knees will be lifted as high as possible in such a manner that both feet should be at one time be above the ground ii) jumping jack exercise in which a simultaneous movement of upper and lower limb will be performed in a manner that every time during a jump the arms were thrusted over the head while the foot moved out to the side and than returning back to the original position 10 repetitions of both the exercises were performed. dynamic resistance exercise modified wingate protocol that incorporates 20 minutes of training on a cycle ergometer; included one minute of cycling with resistance to be performed at 85% to 90% of maximal heart rate (mhr) followed by one minute of cycling with no resistance. the protocol will be performed for 10 times for a duration of 20 minute of workout. cool down the process of cool down last for 5-10 minutes. during this low intensity, long hold stretching were performed of lower limb and upper limb that included shoulder, calf and hamstring stretch

Eligibility criteria:
inclusion criteria: * • class i obese population bmi 30 -39.9 * young adults of age 20-40 years * male and female population exclusion criteria: * • recent surgery that limits participation in exercise program * known cardia disease * any comorbidity that limits participation in training program
placental transfusion in the 'natural' delivery: effect of early and late umbilical cord clamping

Conditions: Hematocrit Anemia; Acidosis

Summary: the investigators conducted a randomized controlled trial (parallel group study with 1:1 randomisation) comparing early cord clamping (ecc, at 60 seconds) and delayed cord clamping (dcc, at 180 seconds) in 90 cases of 'normal', two-step vaginal deliveries. dcc may result in a higher blood volume in the newborn, facilitating the maternal-placental-fetal exchange of circulating compounds, without potentially detrimental acidosis.

introduction: placental transfusion supports an important blood transfer to the neonate, promoting a more stable transition from fetal to extrauterine life, with the potential to prevent iron deficiency in young children. several studies have demonstrated that cord clamping timing is greatly relevant for facilitate placental transfusion, the transfer of extra blood from the placenta to the infant in the third stage of labor. therefore, during' natural', 'two-step delivery umbilical cord management may play a relevant role on blood passage to the neonate and it may affect neonatal hematological values (placental transfusion). the most effective way to manage umbilical cord in in 'natural', two-step delivery remains to be established. objective: the aim of the present study is to evaluate the effect of two different methods of umbilical cord management ecc vs. dcc) on the placental transfusion, defined by δ haematocrit (hct) from arterial cord blood at birth and capillary blood at 48 h of age, accounting for physiological body weight decrease. secondary outcome included contemporary estimate of ph in arterial cord blood gas analysis at birth. material and methods: this is a randomized clinical trial on the effect of different cord management in newborns by 'natural', two-step delivery. after obtaining parental consent, all mothers \> 38 weeks' gestation will be assigned to either ecc or dcc group in a 1:1 ratio, according to a randomized sequence generated by an opened, sealed, numbered, opaque envelope containing the cord clamping interventions allocation, ecc (at 1 minute) or dcc (at 3 minutes after delivery).

Eligibility criteria:
inclusion criteria: vaginal delivery exclusion criteria: cesarean delivery

Keywords: placental transfusion natural, two-step delivery early cord clamping delayed cord clamping
safety and efficacy study of nitric oxide for inhalation on chronic lung disease in premature babies

Conditions: Lung Disease

Summary: the purpose of this study is to assess the safety and efficacy of inhaled nitric oxide to reduce the risk of chronic lung disease in pre-term infants with respiratory distress, and to assess the long-term effects of the therapy on the development of these children over 7 years of clinical follow-up.

although the effects of inhaled nitric oxide on pulmonary vascular tone are well-described and relevant to term infants with persistent pulmonary hypertension, the pathophysiology of respiratory failure in preterm infants may be quite different. chronic lung disease (cld) represents the final pathway of a heterogeneous group of pulmonary disorders of infancy that usually start in the neonatal period. cld most commonly occurs in preterm (\<30 weeks of gestational age (ga) infants with birth weights less than 1,500 grams (g), and especially in those very preterm (\<26 weeks ga) with birth weights less than 1,000 g, and who have been treated for respiratory distress syndrome (rds).

Eligibility criteria:
inclusion criteria: * inborn preterm infants 24+0 weeks-28+6 days weeks gestational age (defined by first trimester ultrasound or if not available based on the last menstrual period) who requires the use of surfactant within 24 hours of birth (either prophylactically, or for signs of developing respiratory distress), or who requires the use of continuous positive airway pressure (cpap) (fraction of inspired oxygen concentration (fio2) ≥ 0.30 on a mean airway pressure ≥ 4cm water (h2o)) within 24 hours of birth in order to maintain an oxygen saturation (spo2) ≥ 85%. * informed consent of the guardian. exclusion criteria: * outborn infants. * infants ≥ 29 weeks gestational age. * infants requiring fio2 \>0.5 to maintain spo2 \>85%, on a sufficient mean airway pressure (e.g., \> 8 cm h2o on controlled mechanical ventilation (cmv)) in order to achieve adequate chest inflation (8-9 ribs on chest x-ray) two hours after the proper administration of exogenous surfactant. * any suspected congenital heart disease other than patent ductus arteriosus or atrial septal defect. * any infant with severe bleeding or coagulation abnormalities at high-risk of diathesis, e.g., platelet \<50,000 per millimeter cube (mm³), fibrinogen \<0.5 gram per liter (g/l), other clotting factors \<10%. * any infant in whom a decision has been made not to provide full treatment, e.g., chromosomal abnormalities, severe multiple abnormalities, severe birth asphyxia, etc. * use of another investigational drug or device before or during the active study period.

Keywords: preemie, inhaled nitric oxide
respiratoy muscle strength in patients with multiple system atrophy

Conditions: Multiple System Atrophy

Summary: the purpose of this study is; compare respiratory function parameters and respiratory muscle strength in patients with msa compare to healthy controls, and to evaluate the results of snip and pimax in measuring inspiratory muscle strength in msa patients.

multiple system atrophy (msa) is a sporadic, neurodegenerative disease that begins in adulthood, progressive, unexplained. brain stem degeneration is thought to play a role in respiratory symptoms such as stridor, sleep-related respiratory disturbances and respiratory failure in msa patients. respiratory disorders were emphasized and evaluated in msa during the studies. however, the pattern of pulmonary anomalies or the performance of the inspiratory muscles is not well defined in the msa. inspiratory muscle strength is assessed by voluntary or involuntary tests. the most commonly used reference values are the known maximal inspiratory mouth pressure (pimax) measurement for ease of use. in people with neuromuscular disease, the influence of the orofacial muscles can cause air leakage from the mouth. as a result, low values may be due to air escape which caused by true respiratory muscle weakness, submaximal effort or weakness of the facial muscles. the purpose of this study is; compare respiratory function parameters and respiratory muscle strength in patients with msa compare to healthy controls, and to evaluate the results of snip and mip in measuring inspiratory muscle strength in msa patients. for this purpose; demographic information (sex, age, occupation, height, body weight ...), clinical and medical status, diagnosis date and mini mental status scale data of all participants will be recorded at the visit. inspiratory muscle strength will be evaluated with sniff nasal inspiratory pressure and maximal inspiratory mouth pressure. expiratory muscle strength will be evaluated with maximal expiratory mouth pressure (pemax).

Eligibility criteria:
inclusion criteria: * being between 40-80 years old * have been diagnosed with msa * being under drug treatment * being enlightened to participate in the study and filling in the consent form * respiratory disease or no history of occupational exposure to affect the respiratory system * the absence of any physical or mental disability that will prevent the implementation of the tests * mini mental test score\> 24 exclusion criteria: * any history of neuromuscular disease other than msa * having a diagnosis of psychiatric illness * chronic obstructive pulmonary disease (copd) diagnosis * the patient is not cooperative * dementia * nasal congestion

Keywords: multiple system atrophy respiratory muscle strength sniff nasal inspiratory pressure
skin pigment/pulse oximeter in congenital heart disease (chd)

Conditions: Hypoxemia; Skin Pigment; Congenital Heart Disease

Summary: recent retrospective studies have demonstrated differences between pulse oximeter values (spo2) and measured arterial oxygen saturation (sao2) in patients identifying as black or hispanic. these retrospective studies have limitations because self-reported race is likely not an accurate metric for level of skin pigmentation and the retrospective nature of these studies may impact the accuracy of simultaneous measures of arterial oxygen saturation and pulse oximeter values. the few prospective studies that have evaluated this issue have utilized color-matching techniques to quantify skin pigmentation, and fewer studies have directly measured skin pigmentation in relation it to pulse oximeter accuracy. the aim of this study is to prospectively measure pulse oximeter accuracy in relation to measured levels of skin pigmentation in the congenital heart disease population.

this is a prospective observational study aiming to evaluate the relationship between pulse oximeter accuracy to the measured level of skin pigmentation in pediatric patients with congenital heart disease (chd). these patients live with varying levels of hypoxemia, making them an ideal study population to investigate this critical patient safety issue. the study population will be pediatric patients (age \<18 years old) with a diagnosis of congenital heart disease presenting for cardiac surgery at the mount sinai hospital. these patient's will undergo surgery as per protocol, as if they were not in a research study, but will have their skin pigment measured using a non-invasive device (color spectrophotometer) prior to surgery. as part of the normal surgery protocols, arterial blood gas samples will be completed. the measured oxygen levels (sao2) on arterial blood gas will be compared to the pulse oximeter value using simultaneous measurements to ensure the measures are concurrent. after cardiopulmonary bypass is initiated for the surgery, the subject's involvement in the study will be completed.

Eligibility criteria:
inclusion criteria: * pediatric patients (age less than 18 years old) with a diagnosis of chd (cyanotic or acyanotic) who are presenting for cardiac surgery under general anesthesia with planned arterial access. exclusion criteria: * age greater than 18 years old * emergency surgery * significant preoperative anemia (hemoglobin \<8.0 g/dl) * preoperative hemodynamic instability (i.e., \>1 vasoactive infusions or mechanical circulatory support) * the presence of any colored nail polish on the planned site of pulse oximeter placement, planned use of any intravenous dyes intraoperatively, and patient, parent, or guardian refusal.

Keywords: pulse oximetry skin pigment congenital heart disease hypoxemia
a clinical trial to evaluate the tolerability and pharmacokinetics of ckd-348

Conditions: Hypertension and Dyslipidemia

Summary: a clinical trial to evaluate the pharmacokinetics and tolerability of ckd-348

an open label, randomized, single dose, 2-sequence, 4-period, cross-over clinical trial to evaluate the pharmacokinetics and tolerability of ckd-348 with coadministration of ckd-828, d097 and d337 in healthy adult volunteers

Eligibility criteria:
inclusion criteria: 1. healthy adult volunteers aged ≥ 19 years 2. weight ≥50kg (man) or 45kg (woman), with calculated body mass index (bmi) of 18 to 30 kg/m2 3. those who meet the blood pressure criteria during screening tests: * systolic blood pressure: 90 to 139 mmhg * diastolic blood pressure: 60 to 89 mmhg 4. those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings. 5. those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and 12-lead ecg results at screening. 6. those who agree to contraception during the participation of clinical trial. 7. individuals who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial. exclusion criteria: 1. those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs. 2. those who take barbiturate and any related drugs which may cause induction or inhibition of drug metabolism within 1 month before the first administration of investigational products. 3. those who donated whole blood or apheresis within 2 months or 1 month respectfully, or received blood transfusion within a month. 4. those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery. 5. those who exceed an alcohol and cigarette consumption than below criteria * alcohol: man_21 glasses/week, woman_14 glasses/week (1 glass: soju 50ml, wine 30ml, or beer 250ml) * smoking: 20 cigarettes/day 6. those who have any history of diabetic mellitus, nephropathy, biliary obstruction, shock, angioedema, cardiac insufficiency, dihydropyridine sensitivity, unstable angina, hypothyroidism. 7. those who have genetic problems such as galactose intolerance, lapp lactose deficiency or glucose-galactose malabsorption. 8. those who are deemed insufficient to participate in this clinical study by investigators. 9. woman who are pregnant or breastfeeding.
gallium ga 68 dota-neobomb1 and gallium ga 68 psma-r2 pet/mri in diagnosing participants with recurrent prostate cancer

Conditions: Prostate Adenocarcinoma; PSA Progression; Recurrent Prostate Carcinoma

Summary: this phase ii trial studies how well gallium ga 68 dota-neobomb1 and gallium ga 68 psma-r2 positron emission tomography (pet)/magnetic resonance imaging (mri) work in diagnosing participants with prostate cancer that has come back. diagnostic procedures, such as gallium ga 68 dota-neobomb1 and gallium ga 68 psma-r2 pet/mri, may help find and diagnose prostate cancer and find out how far the disease has spread.

primary objectives: i. to evaluate gallium ga 68 dota-neobomb1 (68ga-neobomb1) and gallium ga 68 psma-r2 (68ga-psma r2) pet/mri for detection of recurrent prostate cancer after initial therapy in patients meeting the criterion of biochemical recurrence. outline: participants are randomized to 1 of 2 arms. arm i: participants receive gallium ga 68 dota-neobomb1 intravenously (iv) and 45 minutes later, undergo pet/mri. within 2 weeks, participants receive gallium ga 68 psma-r2 iv then undergo pet/mri 45-60 minutes later. arm ii: participants receive gallium ga 68 psma-r2 iv and 45-60 minutes later undergo pet/mri. within 2 weeks, participants receive gallium ga 68 dota-neobomb1 iv then undergo pet/mri 45 minutes later. after completion of study, participants are followed up at 12 months.

Eligibility criteria:
inclusion criteria: * biopsy proven prostate adenocarcinoma. * rising prostate-specific antigen (psa) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy). a. post radical prostatectomy (rp) - american urological association (aua) recommendation. (i) psa greater than 0.2 ng/ml measured after at least 6 weeks from radical prostatectomy. (ii) confirmatory persistent psa greater than 0.2 ng/ml (total of two psa measurements greater than 0.2 ng/ml). b. post-radiation therapy ? american society for therapeutic radiology and oncology (astro)-phoenix consensus definition. (i) a rise of psa measurement of 2 or more ng/ml over the nadir. * able to provide written consent. * karnofsky performance status of \>= 50 (or eastern cooperative oncology group \[ecog\]/world health organization \[who\] equivalent). exclusion criteria: * inability to lie still for the entire imaging time. * inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.). * any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance. * known allergy, hypersensitivity, or intolerance to the investigational product or its excipients. * metallic implants (contraindicated for magnetic resonance imaging \[mri\]).
efficacy of suction enabled retraction device

Conditions: Surgical Blood Loss; Spinal Surgery

Summary: this is a prospective randomized controlled trial of the suction-integrated surgical tissue elevator \& retractor \[sister\] device to assess: * effects on operative time and efficiency of exposure in open lumbar spine cases. * effect on total blood loss during the exposure part of the operation. * rate of clogging of suction device.

the device, suction-integrated surgical tissue elevator \& retractor \[sister\], is shaped like a cobb elevator but also has a hollow core allowing suction tubing to be connected. thus, a single hand can be used to retract and suction at the same time while the other hand separates soft tissue from the bones with electrocautery. this set up which is proposed to be more efficient will be evaluated in this study.

Eligibility criteria:
inclusion criteria: * english speaking * patients undergoing lumbar one to sacral one open instrumentation * surgery performed by the departments of neurological surgery and orthopedics at the university of miami miller school of medicine exclusion criteria: * less than 22 years old * procedure does not involve instrumentation * prior lumbar spine surgery involving more than one level * bmi less than 20 or greater than 35 * known bleeding conditions ( ex. factor v leiden, von willebrand) * routinely taking anticoagulation medicine (ex. aspirin 325 mg/day, plavix) * operative cases where a single surgeon performs both sides of exposure * pregnant women * prisoners * adults unable to consent

Keywords: open lumbar spine surgery operative time and efficiency suction-integrated surgical tissue elevator and retractor
management of patients with neovascular age-related macular degeneration undergoing cataract surgery

Conditions: Wet Macular Degeneration; Cataract Extraction

Summary: to-date there have been only very few studies to examine the effect of cataract surgery to patients with wet age-related macular degeneration. the evidence on the effects of cataract surgery in such patients suggests improvement of their visual function and quality of life, but at the same time a subclinical susceptibility to macular edema and exacerbation of the choroidal neovascularization. therefore it is highly important to identify the optimum treatment regime, pursuing the best anatomical and functional postoperative results.

to-date there have been only very few studies to examine the effect of cataract surgery to patients with neovascular age-related macular degeneration (amd), especially in the era of anti-vascular endothelial growth factor (anti-vegf) therapy. furthermore the issue of optimum treatment regimen that should be used in the peroperative period has never been addressed. since the human life expectancy gradually increases, the number of patients who are under anti-vegf intravitreal injections for wet amd will be increasing accordingly. cataract surgery in such patients, despite guarded prognosis has been proved to improve their visual function and quality of life. on the other hand, it has been shown that cataract surgery induces anatomic changes based on optical coherence tomography analysis, suggesting a subclinical susceptibility to postoperative cystoid macular edema or exacerbation of choroidal neovascularization. therefore it is highly important to identify the optimum treatment regime, pursuing the best anatomical and functional postoperative results.

Eligibility criteria:
inclusion criteria: * active choroidal neovascularization (at least 1 intravitreal injection in the past 12 months) associated with amd and involving the foveal center * bcva of 1.0 (logmar) or better * duration of wet amd less than 3 years exclusion criteria: * coexisting ocular pathology potentially affecting visual acuity and/or status of the macula including diabetic retinopathy, advanced glaucoma, retinal vein occlusion, retinal detachment * newly diagnosed patients with wet amd who are on anti-vegf treatment for less than 6 months